All In Biotech

Drug Trial Radar · NCT02254967

A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population

A Phase IIIB/IV Randomized, Controlled, Open-label, Parallel Group Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration Fidaxomicin Therapy in the Sustained Clinical Cure of Clostridium Difficile Infection in an Older Population

Last checked: Nov 19, 2026Latest source record: Oct 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 364 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

364

Actual

Start

Nov 6, 2014

Primary completion

Mar 27, 2016

Study completion May 5, 2016

Sponsor

Lead sponsor
Astellas Pharma Europe Ltd.Astellas (ALPMY)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Oct 2, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of the study is to evaluate whether the extended duration fidaxomicin therapy is superior to the standard vancomycin therapy in sustained clinical cure of CDI at 30 days after end of treatment (Day 40 or Day 55).

Conditions

  • Clostridium Difficile

Interventions

  • FidaxomicinDrug

    oral tablets administered in an extended pulsed regimen

  • VancomycinDrug

    oral capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with a Sustained Clinical Cure of CDI at 30 Days after End of TreatmentTime frame: Day 40 (for vancomycin) and day 55 (for fidaxomicin extended pulsed regimen [EPFX])

Locations

109 sites in 22 countries. Site status is shown where the registry gives one.

  • Site AT43002

    Graz, Austria

  • Site AT43003

    Linz, Austria

  • Site AT43001

    Salzburg, Austria

  • Site BE32007

    Aalst, Belgium

  • Site BE32006

    Bruges, Belgium

  • Site BE32001

    Brussels, Belgium

  • Site BE32005

    Brussels, Belgium

  • Site BE32008

    Liège, Belgium

  • Site HR38506

    Osijek, Croatia

  • Site HR38503

    Rijeka, Croatia

  • Site HR38505

    Zadar, Croatia

  • Site HR38501

    Zagreb, Croatia

  • Site CZ42002

    Brno-Bohunice, Czechia

  • Site CZ42005

    Kyjov, Czechia

  • Site CZ42004

    Opava, Czechia

  • Site CZ42003

    Prague, Czechia

  • Site CZ42001

    Praha 8 - Libeň, Czechia

  • Site DK45001

    Herlev, Denmark

  • Site DK45005

    Hillerød, Denmark

  • Site DK45004

    Nykøbing Falster, Denmark

  • Site FI35801

    Helsinki, Finland

  • Site FI35802

    Turku, Finland

  • Site FR33003

    Bordeaux, France

  • Site FR33008

    Clermont-Ferrand, France

  • Site FR33006

    Lille, France

  • Site FR33005

    Nantes, France

  • Site FR33004

    Nîmes, France

  • Site FR33001

    Paris, France

  • Site FR33007

    Paris, France

  • Site FR33002

    Rennes, France

  • Site FR33009

    Saint-Priest-en-Jarez, France

  • Site DE49001

    Cologne, Germany

  • Site DE49011

    Cologne, Germany

  • Site DE49012

    Hamburg, Germany

  • Site DE49006

    Leipzig, Germany

  • Site DE49016

    Lübeck, Germany

  • Site DE49008

    Marburg, Germany

  • Site GR30005

    Athens, Greece

  • Site GR30008

    Athens, Greece

  • Site GR30001

    Athens, Greece

Showing 40 of 109 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.